What Eikons modest IPO says about the future of bigmoney bigname biotech Endpoints News

Andrew Dun...

For Eikon Ther­a­peu­tics, its IPO feels more like some­thing its sur­viv­ing rather than cel­e­brat­ing. The Bay Area start­up is one of biotechs most promi­nent pri­vate­lyRead More

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *